$18.63
0.96% yesterday
Nasdaq, Oct 01, 10:00 pm CET
ISIN
US91678A1079
Symbol
UPB

Upstream Bio Stock price

$18.63
+1.50 8.76% 1M
+11.93 178.06% 6M
+2.19 13.32% YTD
+1.63 9.59% 1Y
+1.63 9.59% 3Y
+1.63 9.59% 5Y
+1.63 9.59% 10Y
+1.63 9.59% 20Y
Nasdaq, Closing price Wed, Oct 01 2025
-0.18 0.96%
ISIN
US91678A1079
Symbol
UPB
Industry

Key metrics

Basic
Market capitalization
$1.0b
Enterprise Value
$620.5m
Net debt
positive
Cash
$393.6m
Shares outstanding
53.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
372.8 | 374.6
EV/Sales
228.1 | 229.2
EV/FCF
negative
P/B
2.5
Financial Health
Equity Ratio
97.5%
Return on Equity
-16.3%
ROCE
-29.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.7m | $2.7m
EBITDA
$-121.4m | $-160.6m
EBIT
$-121.6m | $-166.6m
Net Income
$-110.1m | $-151.5m
Free Cash Flow
$-114.5m
Growth (TTM | estimate)
Revenue
- | 14.2%
EBITDA
- | -106.7%
EBIT
- | -114.3%
Net Income
- | -98.3%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
-4,459.2% | -5,932.4%
EBIT
-4,464.6%
Net
-4,041.8% | -5,595.4%
Free Cash Flow
-4,206.2%
More
EPS
$-2.0
FCF per Share
$-2.1
Short interest
10.1%
Employees
-
Rev per Employee
-
Show more

Is Upstream Bio a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Upstream Bio Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Upstream Bio forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Upstream Bio forecast:

Buy
88%
Hold
13%

Financial data from Upstream Bio

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2.72 2.72
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
-
861%
- Research and Development Expense 101 101
-
3,708%
-121 -121
-
-4,464%
- Depreciation and Amortization 0.15 0.15
-
6%
EBIT (Operating Income) EBIT -122 -122
-
-4,470%
Net Profit -110 -110
-
-4,046%

In millions USD.

Don't miss a Thing! We will send you all news about Upstream Bio directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Upstream Bio Stock News

Neutral
GlobeNewsWire
2 days ago
– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor complexes – – Data support the potential of verekitug's unique mechanism of action to achieve a differentiated therapeutic effect across a broad range of TSLP-driven severe respirato...
Neutral
GlobeNewsWire
23 days ago
WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on ...
Neutral
Seeking Alpha
24 days ago
Upstream Bio, Inc. - Special Call Company Participants Meggan Buckwell E. Sutherland - CEO & Director Aaron Deykin - Chief Medical Officer and Head of Research & Development Conference Call Participants Tessa Romero - JPMorgan Chase & Co, Research Division Yaron Werber - TD Cowen, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Matthew Phipps - William Blair & Company ...
More Upstream Bio News

Company Profile

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Head office United States
CEO E. Sutherland
Website upstreambio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today